13 January 2024
Changes in the standard of care have led to some interest in abandoning surgical nodal staging via the sentinel lymph node biopsy procedure in melanoma patients. According to this recent article, while it is certainly possible that additional changes in melanoma therapy will make sentinel lymph node biopsy obsolete in the future, at present it remains a minimally invasive, low morbidity means of improving both staging and outcomes.
13 January 2024
Immune checkpoint inhibitors are frequently associated with the development of immunotherapy-related adverse events (irAEs). The exact etiology, including the role of environmental factors, remains incompletely understood. According to this recent study, environmental factors that are associated with particular seasons may contribute to the development of certain irAEs and suggest the potential effect of environmental triggers. The identification of these factors may enhance preventive and therapeutic strategies to reduce the morbidity of irAEs.
13 January 2024
Authors of this manuscript critically reviewed the most updated literature data on the landscape of predictive factors in metastatic melanoma treated with immune checkpoint inhibitors (ICIs). They focus on the principal limits and potentiality of different methods, shedding light on the more promising biomarkers.
12 January 2024
According to this study, community pharmacies can play a positive role in skin cancer counseling. A broad range of citizens was reached and triggered to purchase sunscreen, often on the same day as the counseling. Citizens receiving additional counseling were more likely to visit a dermatologist within 180 days.
17 December 2023
According to this recent study, key informants in Australia were supportive in principle of risk-tailored melanoma screening (versus opportunistic screening). Considerations around risk assessment, policy and modelling the costs of current versus future approaches will help inform possible future implementation of risk-tailored population screening for melanoma.
17 December 2023
The aim of this recent study was to develop a risk-scoring classifier-based algorithm to estimate the probability of an atypical pigmented facial lesion (aPFL) being malignant. The study concludes that the facial iDScore model can be proposed as a feasible tool for managing patients with aPFLs.
17 December 2023
The phase 3, double-blind CheckMate 76K trial assessed 790 patients with resected stage IIB/C melanoma randomized 2:1 (stratified by tumor category) to nivolumab 480 mg or placebo every 4 weeks for 12 months. The study concludes that nivolumab is an effective and generally well-tolerated adjuvant treatment in patients with resected stage IIB/C melanoma.
17 December 2023
This study aimed to determine the demographics and socioeconomic disease trends of non-melanoma skin cancer (NMSC) prevalence in New Zealand over the last 15 years. According to its findings, NMSC imposes a significant disease burden on New Zealand, and the probability of developing skin cancer increases with age. The study concludes that more effective skin cancer prevention and treatment is needed.
17 December 2023
Global dermoscopy experts have explored the topic of melanoma overdiagnosis and the way forward.
16 December 2023
According to this recent study, the World Health Organization and the International Labour Organization estimate that occupational exposure to ultraviolet radiation is common and causes substantial, inequitable and growing attributable burden of non-melanoma skin cancer. Governments must protect outdoor workers from hazardous exposure to UVR and attributable NMSC burden and inequalities.
